The European Association for Veterinary Pharmacology and Toxicology is an association that promotes the disciplines of veterinary pharmacology, toxicology and therapeutics. EAVPT aims to promote education and research in the fields of veterinary pharmacology and toxicology. It achieves these aims through organizing congresses, workshops, symposia or other scientific and educational meetings. In addition, EAVPT enhances the exchange of education materials, ideas and teachers between veterinary institutes. In addition, EAVPT organizes committees of experts to make recommendations on current problems in veterinary pharmacology, toxicology and therapeutics, including concerns in relation to human and environmental health. EAVPT has members from around the world and hosts an international congress every 3 years.
EXECUTIVE COMMITTEE
Dr. Mochel obtained his Veterinary Medical Degree from the National Veterinary School of Alfort. He completed his Doctorate studying Neurosciences in collaboration with the College de France, and received the Silver Medal from Paris XII for his work. Dr. Mochel holds a MS in Pharmacology and Pharmacokinetics and is a Diplomate of the European College of Veterinary Pharmacology and Toxicology (ECVPT).
He completed his Ph.D at Leiden University, with a focus on the mathematical modeling of the renin-angiotensin system for cardiovascular diseases. He is a founder of the Animal Health Modeling & Simulation Society which aims at promoting the dissemination of mathematical modeling in Veterinary Sciences.
Dr. Mochel is an Associate Professor in the Department of Biomedical Sciences at Iowa State University (ISU) and the Chair of the Education and Residency Committee of the ECVPT. He is a Fellow of the American Academy of Veterinary Pharmacology and Therapeutics and the current Vice-President of the European Association of Veterinary Pharmacology and Toxicology. His research pertains to the analysis of clinical data obtained from spontaneous animal models of human diseases to bridge the knowledge gap between experimental models and patients.
He has authored 70 peer-reviewed publications in select biomedical journals and was the 2019 recipient of the ISU Early Career Achievement in Research Award at the College of Veterinary Medicine.
BVM&S, MBBS, DVMS, PhD, DipECVPT, PGCert (Business Admin), CBiol, FRACGP, FRSB, FRCVS is Professor of One Health at the University of Sunshine Coast in the Faculty of Science, Health, Education and Engineering in Queensland, Australia.
Until recently he was also an Adjunct Professor at the Institute of Health and Biomedical Innovation at the Queensland University of Technology and a Principal Research Fellow at the flagship Translational Research Institute in Brisbane. He is a former Dean of the Queensland Veterinary College and Director of European Union Research and Development with Elanco Animal Health. He is a Diplomate of the European College of Veterinary Pharmacology and Toxicology, President of the European Association of Veterinary Pharmacology and Toxicology and President of the Australasian Society of Biology.
He was previously an owner of one of the larger veterinary groups in the UK and still keeps up clinical practice skills as both a veterinarian and medical doctor working in General Medical Practice in a busy clinic in the Western Suburbs of Brisbane. He is passionate about One Health and disease management, having over his career worked in over 100 countries on projects related to human and animal health has project managed the registration of over 60 veterinary products internationally with FDA, EMEA, NZFSA, APVMA and other registration agencies. His research has involved human and animal disease solutions including some of the sentinel developments in macrolide antibiotic therapies for which he was recognized with a Fellowship of the Royal Society of Biology in UK, Fellowship of the Royal College of Veterinary Surgeons and as an Illustrious Fellow of the Royal Academy of Veterinary Sciences in Spain where he has remains an International Collaborator at the Universidad de Complutense in Madrid. His current interests focus particularly on translational pharmacological and health related developments relevant to man, animals and increasingly - to the environment. This includes antimicrobial resistance modelling and health economics.
Mathias Devreese graduated as veterinarian at Ghent University (Belgium). He is currently associate professor of veterinary pharmacology at the same institution. He has previously worked as research fellow at the Department of Animal Biosciences at Guelph University (Canada) and the Institute of Computational Comparative Medicine at Kansas State University (US). With >100 peer reviewed articles his research focuses on bioanalysis of drugs as well as other xenobiotics and drug pharmacokinetics in a wide array of animal species.
He is board certified as Diplomate of the European College of Veterinary Pharmacology and Toxicology (ECVPT) and member of the Examination Committee of the College. He is fellow and former Executive Committee member of the American Academy of Veterinary Pharmacology and Therapeutics (AAVPT). He also serves as an associate editor for BMC Veterinary Research (Pharmacology and Toxicology section) and Scientific Board member of the Journal of Veterinary Pharmacology and Therapeutics. In 2023, he hosted the 15th International Congress of the EAVPT in Bruges, Belgium.
Dipl. ECVPT is Professor and Executive Director at the Institute of Pharmacology and Toxicology, Department of Veterinary Medicine at the Freie Universität in Berlin since July 2017. Dr. Bäumer received his doctoral degree from the University of Veterinary Medicine in Hannover, Germany in 1999 and his postdoctoral lecture qualification (Dr. med. vet. habil.) for Pharmacology and Toxicology in 2007. He was endowed Associate Professor for Veterinary Dermato-pharmacology from 2008 to 2012. Then he became Associate Professor of Pharmacology at the College of Veterinary Medicine, NC State University, USA (2013-2017).
The research focus of his group is in the field of immune-pharmacology. Currently, pharmacological targets like the histamine H4 receptor and JAK-STAT-inhibitors are studied with emphasis on treating allergic skin diseases and its associated itch. He has authored 90 peer-reviewed publications, several with particular focus on dermato-pharmacology.
Dr Aude Ferran
